Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

ROCHE HOLDING LTD. (ROG)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Sector news Pharmaceuticals - NEC
12:18a Judge Signals He Will Approve $290 Million Settlement Between Allergan Shareh..
01/16 CELGENE : in Talks to Buy Juno Therapeutics -- Update
01/16 CELGENE : in Talks to Buy Juno Therapeutics
01/16 Judge Signals He Will Approve $290 Million Settlement Between Allergan Shareh..
01/16 Health-conscious Nestle sells U.S. candy to Ferrero for $2.8 billion
01/16 ORGANIGRAM : Canopy Growth to supply cannabis to Prince Edward Island
01/15 Drugmaker Dermapharm gears up for likely first German IPO of 2018
01/12 Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/12 SPARK'S PRICE FOR LUXTURNA BLINDNESS : Icer
01/12 ASTRAZENECA : Receives FDA Approval for Breast Cancer Treatment
01/12 WPP Buys London-based Mash Strategy
01/12 TEVA PHARMACEUTICAL INDUSTRIES : Ohio Talks Settlement Of Opioid Lawsuits -- WSJ
01/11 JOHNSON & JOHNSON : Ohio Takes Steps Toward Resolution of Opioid Litigation
01/11 JOHNSON & JOHNSON : Ohio in Talks to Settle Opioid Suit, State Attorney General ..
01/11 Bayer raises higher than expected 1.8 billion euros from Covestro placement
01/11 BAYER : Reduces Direct Stake in Covestro to 14.2%
01/10 Bayer to sell Covestro shares worth about $1.8 billion
01/10 Bond sell-off hits European shares but boost banks
01/10 BAYER : Further Reduces Stake in Covestro
01/10 TEVA PHARM DIRECTORS CUT THEIR SALAR : board member
01/10 TEVA PHARMACEUTICAL INDUSTRIES : Pharm directors cut their salaries in half - bo..
01/10 Nestle frontrunner for Merck KGaA's consumer health business - Bloomberg
01/10 BAYER : J&J win reversal of $28 million verdict in Xarelto lawsuit
01/09 BOSTON SCIENTIFIC : Health Care Up On Earnings Optimism -- Health Care Roundup
01/09 GLAXOSMITHKLINE : GSK CEO says looking at Pfizer consumer business, but not a pr..
01/09 U.S. pharma executives expect deals to pick up after tax overhaul
01/09 Drug Firm Rejects $3.13 Billion Offer From Novo Nordisk -- WSJ
01/09 Drug Industry Isn't Giving Up on Alzheimer's
01/08 SHIRE : cuts 2020 revenue target, prepares for spin-off of ADHD drugs
01/08 Ablynx soars after rejects Novo Nordisk's $3.1 billion biotech bid
01/08 European shares hit highest since August 2015, Ablynx soars
01/08 Weak results weigh on FTSE 100, profit warning pummels Mothercare
01/08 SHIRE : Announces Reorganization; Sets $17 Billion-$18 Billion Revenue Target
01/08 $11 billion biotech binge fuels forecasts of 2018 M&A surge
01/08 AXOVANT SCIENCES : shares plunge after key dementia drug programme scrapped
01/08 SANOFI : and Regeneron boost investment in cancer drug cemiplimab
01/08 Belgium's Ablynx Rejects EUR2.6 Billion Bid From Novo Nordisk
01/08 SHIRE : Shire Announces Business Update At 36th -2-
01/08 SHIRE : Shire Announces Business Update At 36th Annual J.P. Morgan Healthcare Co..
01/08 CELGENE : to buy Impact Biomedicines for up to $7 billion
01/07 CELGENE : Nears Deal to Buy Impact Biomedicines, Sources Say -- Update
01/07 ALNYLAM PHARMACEUTICALS : Sanofi Restructure RNAi Rare-Disease Alliance -- Updat..
01/07 ALNYLAM PHARMACEUTICALS : Sanofi Restructure RNAi Rare-Disease Alliance
01/07 CELGENE : Nears Deal to Buy Impact Biomedicines for as Much as $7 Billion -- Sou..
01/07 SANOFI : Safety Fears Threaten Global Dengue Vaccine Effort
01/06 PFIZER : Ends Hunt for Drugs to Treat Alzheimer's and Parkinson's
01/06 BRISTOL MYERS SQUIBB : Cites Tax Impact -- WSJ
01/06 BRISTOL MYERS SQUIBB : to Take $3 Billion Charge Related to Tax Overhaul
01/06 BRISTOL MYERS SQUIBB : Myers sees $3 billion tax hit in fourth quarter 2017
01/05 CONSTELLATION BRANDS : third quarter sales miss, no hit from legalized pot
Financials ( CHF)
Sales 2017 53 552 M
EBIT 2017 18 174 M
Net income 2017 11 159 M
Debt 2017 9 887 M
Yield 2017 3,52%
P/E ratio 2017 18,24
P/E ratio 2018 16,72
EV / Sales 2017 4,11x
EV / Sales 2018 3,88x
Capitalization 210 B
Sector Pharmaceuticals - NEC
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.-0.85%218 350
JOHNSON & JOHNSON4.32%391 587
NOVARTIS1.38%225 838
PFIZER0.88%217 804
MERCK AND COMPANY4.25%159 987
AMGEN6.41%134 322
SANOFI1.88%113 491
NOVO NORDISK A/S0.07%108 273
BAYER0.48%106 071
BRISTOL-MYERS SQUIBB COMPANY2.50%102 801
ABBOTT LABORATORIES3.10%102 417
ELI LILLY AND COMPANY2.98%95 773
GLAXOSMITHKLINE2.31%92 553
ASTRAZENECA0.18%89 569
CELGENE CORPORATION1.57%83 456
ALLERGAN PLC7.62%58 551
TAKEDA PHARMACEUTICAL CO LTD-0.83%45 814
SHIRE-9.33%44 160
JIANGSU HENGRUI MEDICINE CO LTD7.99%32 608
CHUGAI PHARMACEUTICAL CO LTD0.69%29 088
ASTELLAS PHARMA INC-0.83%26 806